| Project/Area Number |
17K15379
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Veterinary medical science
|
|---|
| Research Institution | Kobe University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 筋萎縮 / 脂質メディエーター / トリブチリン |
|---|
| Outline of Final Research Achievements |
Polyunsaturated fatty acids and all lipid mediators measured were higher in soleus muscles than in extensor digitorum longus, especially pro-inflammatory prostaglandin (PG) E2 and anti-inflammatory resolvin (Rv) E3 (p < 0.01-0.05) before lipopolysaccharide (LPS) injection,. The anti-inflammatory lipid mediators from DHA, RvD5 and protectin D1, were only detected in soleus muscles. LPS injection changed lipid mediators, PGE2 were increased at 6 h after LPS injection in both muscles (p < 0.01). The increased PGE2 may affect muscle atrophy.
Tributyrin, a prodrug of butyrate, suppressed LPS-induced leukotriene B4 (LTB4). Oral tributyrin administration also improved LPS-induced muscle atrophy. Tributyrin may improve muscle atrophy through suppressed LTB4 in endotoxemic rats.
|
| Academic Significance and Societal Importance of the Research Achievements |
骨格筋中の脂質メディエーター解析とそれを根拠にした研究が、侵襲下の急性期筋萎縮にとどまらず、多様な慢性病変や運動時などの広範な筋萎縮の病態や予防・治療法へ発展することが想定される。また、トリブチリンは食品成分であるため、安全に、しかも日常的に摂取することができ、サルコペニアを介する各種病態での予後改善にも作用しうると考えられ、幅広い臨床応用への波及効果が期待できる。
|
